Target Name: ZFP57
NCBI ID: G346171
Other Name(s): ZFP57 variant 1 | ZFP57 zinc finger protein, transcript variant 1 | ZFP57_HUMAN | ZNF698 | zinc finger protein 698 | C6orf40 | zfp-57 | ZFP57 zinc finger protein | Zfp-57 | OTTHUMP00000065879 | Zinc finger protein 57 homolog | Zinc finger protein 698 | bA145L22.2 | Zinc finger protein 57 homolog (isoform 1) | TNDM1 | bA145L22

ZFP57: A Potential Drug Target Or Biomarker for Cancer

ZFP57 (Zinc Finger Protein 57) is a gene that encodes a protein known for its role in various cellular processes. The ZFP57 gene has been identified as a potential drug target or biomarker in the field of cancer, and research is ongoing to determine its potential utility as a therapeutic approach.

The ZFP57 protein is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is characterized by a N-terminus that contains a zinc finger domain, which is known for its ability to interact with other proteins. The ZFP57 protein is also known for its ability to form a complex with the protein p16INK4a, which is a known driver of cancer.

Research has shown that high levels of ZFP57 expression are associated with poor prognosis in various types of cancer, including breast, ovarian, and colorectal cancers. This is thought to be due to the fact that high levels of ZFP57 can promote the growth and survival of cancer cells.

One potential mechanism by which ZFP57 may contribute to cancer growth is by regulating the activity of the PI3K/Akt signaling pathway. The PI3K/Akt pathway is a well-established pathway that is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. High levels of ZFP57 have been shown to inhibit the activity of the PI3K/Akt pathway, which could lead to reduced cell survival and a higher risk of cancer progression.

Another potential mechanism by which ZFP57 may contribute to cancer growth is by regulating the expression of genes involved in cell adhesion and migration. ZFP57 has been shown to be involved in the regulation of the adhesion protein gene (E-cadherin), which is known for its role in cell adhesion and migration. High levels of ZFP57 have been shown to reduce the expression of E-cadherin, which could lead to increased cell mobility and a higher risk of cancer progression.

In addition to its potential role in cancer growth, ZFP57 is also thought to be involved in the regulation of cellular processes that are important for normal tissue function. For example, ZFP57 has been shown to be involved in the regulation of the production of new blood vessels, which is thought to be important for the delivery of oxygen and nutrients to cancer cells.

Given the potential involvement of ZFP57 in various cellular processes, it is an attractive target for drug development. Researchers are currently exploring various small molecules and other compounds that have the potential to inhibit the activity of ZFP57. These compounds are being tested for their ability to restore the activity of the ZFP57 protein and to inhibit its contribution to cancer growth.

While more research is needed to fully understand the role of ZFP57 in cancer, research is ongoing to determine its potential as a drug target or biomarker. If ZFP57 is indeed a drug target, it may be possible to develop compounds that can inhibit its activity and reduce the risk of cancer progression. If ZFP57 is a biomarker, researchers may be able to use it as a diagnostic tool to predict the risk of cancer in individuals.

Overall, ZFP57 is a gene that has significant potential as a drug target or biomarker in the field of cancer. Further research is needed to fully understand its role in cellular processes and to determine its potential utility as a therapeutic approach.

Protein Name: ZFP57 Zinc Finger Protein

Functions: Transcription regulator required to maintain maternal and paternal gene imprinting, a process by which gene expression is restricted in a parent of origin-specific manner by epigenetic modification of genomic DNA and chromatin, including DNA methylation. Acts by controlling DNA methylation during the earliest multicellular stages of development at multiple imprinting control regions (ICRs) (PubMed:18622393, PubMed:30602440). Acts together with ZNF445, but ZNF445 seems to be the major factor in human early embryonic imprinting maintenance. In contrast, in mice, ZFP57 plays the predominant role in imprinting maintenance (PubMed:30602440). Required for the establishment of maternal methylation imprints at SNRPN locus. Acts as a transcriptional repressor in Schwann cells. Binds to a 5'-TGCCGC-3' consensus sequence and recognizes the methylated CpG within this element (By similarity)

More Common Targets

ZFP62 | ZFP64 | ZFP64P1 | ZFP69 | ZFP69B | ZFP82 | ZFP90 | ZFP91 | ZFP91-CNTF | ZFP92 | ZFPL1 | ZFPM1 | ZFPM2 | ZFPM2-AS1 | ZFR | ZFR2 | ZFTA | ZFTRAF1 | ZFX | ZFX-AS1 | ZFY | ZFYVE1 | ZFYVE16 | ZFYVE19 | ZFYVE21 | ZFYVE26 | ZFYVE27 | ZFYVE28 | ZFYVE9 | ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141